Abstract
Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but also in pathological conditions such as inflammation. Since ten years now, it is well known that this enzyme exists under two forms: a constitutive (COX-1) and an inducible form (COX-2). Both enzymes are sensitive to inhibition by conventional nonsteroidal antiinflammatory drugs (NSAIDs). Observations that COX-1, involved in several homeostatic processes, played a housekeeping role while COX-2 expression was associated with inflammation and other pathologies such as cancer proliferation have led to the development of COX-2 selective inhibitors in order to reduce the classical side-effects, of which gastric irritation is the most common, associated with the use of conventional NSAIDs.
Current Medicinal Chemistry
Title: Recent Advances in Inducible Cyclooxygenase (COX-2) Inhibition.
Volume: 7 Issue: 10
Author(s): Xavier de Leval, Jacques Delarge, Fabian Somers, Pascal de Tullio, Yves Henrotin, Bernard Pirotte and Jean-Michel Dogne
Affiliation:
Abstract: Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but also in pathological conditions such as inflammation. Since ten years now, it is well known that this enzyme exists under two forms: a constitutive (COX-1) and an inducible form (COX-2). Both enzymes are sensitive to inhibition by conventional nonsteroidal antiinflammatory drugs (NSAIDs). Observations that COX-1, involved in several homeostatic processes, played a housekeeping role while COX-2 expression was associated with inflammation and other pathologies such as cancer proliferation have led to the development of COX-2 selective inhibitors in order to reduce the classical side-effects, of which gastric irritation is the most common, associated with the use of conventional NSAIDs.
Export Options
About this article
Cite this article as:
de Leval Xavier, Delarge Jacques, Somers Fabian, de Tullio Pascal, Henrotin Yves, Pirotte Bernard and Dogne Jean-Michel, Recent Advances in Inducible Cyclooxygenase (COX-2) Inhibition., Current Medicinal Chemistry 2000; 7 (10) . https://dx.doi.org/10.2174/0929867003374417
DOI https://dx.doi.org/10.2174/0929867003374417 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Electrochemical Biosensors as a Screening Tool of In Vitro DNA-Drug Interaction
Current Pharmaceutical Analysis Adipose Tissue-Derived Multi-lineage Progenitor Cells as a Promising Tool for In Situ Stem Cell Therapy
Current Tissue Engineering (Discontinued) Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued) Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Tyrosine Hydroxylase Gene: Another Piece of the Genetic Puzzle of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Dynamic Role of Microparticles in Type 2 Diabetes Mellitus
Current Diabetes Reviews Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications
Current Nutrition & Food Science Comparison of the Expression and Immunogenicity of Wild-Type and Sequence-Modified HIV-1 gag Genes in a Recombinant Sendai Virus Vector
Current HIV Research Chronic Inflammatory Diseases and the Acute Respiratory Distress Syndrome (ARDS)
Current Pharmaceutical Design Foreword:
Current Pharmaceutical Design Overview of Recent Advances in Injectable Materials for Augmentation of Bone and Soft-Tissue
Recent Patents on Biomedical Engineering (Discontinued) The Update of NGAL in Acute Kidney Injury
Current Protein & Peptide Science Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy
Current Drug Metabolism Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design In Vitro and In Vivo Neuroprotective Effects of Etifoxine in β-Amyloidinduced Toxicity Models
CNS & Neurological Disorders - Drug Targets Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters BX471: A CCR1 Antagonist with Anti-Inflammatory Activity in Man
Mini-Reviews in Medicinal Chemistry